Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Phase 1

Active, not recruiting

Conditions: B-cell Lymphoma Refractory
B-Cell Acute Lymphoblastic Leukemia, Adult
B-cell Lymphoma Recurrent

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: CD19-CD34 CAR transduced T cells

First Posted Date: 2020-01-02

Last Posted Date: 2022-08-15

Lead Sponsor: Loyola University

Target Recruit Count: 24

Registration Number: NCT04214886

Locations: 🇺🇸
Loyola University, Maywood, Illinois, United States

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma
Progressive Disease
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma

Interventions: Biological: Anakinra
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate

First Posted Date: 2019-12-20

Last Posted Date: 2024-12-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT04205838

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Phase 2

Terminated

Conditions: Recurrent Plasma Cell Myeloma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Biological: Daratumumab
Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus

First Posted Date: 2019-12-19

Last Posted Date: 2023-09-28

Lead Sponsor: Srinivas Devarakonda

Target Recruit Count: 1

Registration Number: NCT04205240

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Phase 2

Recruiting

Conditions: Myelodysplasia
Chronic Graft-versus-host-disease
Acute Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Anti-Thymocyte globulin (rabbit)

First Posted Date: 2019-12-18

Last Posted Date: 2023-03-15

Lead Sponsor: McMaster University

Target Recruit Count: 80

Registration Number: NCT04202835

Locations: 🇨🇦
Hôpital de l'Enfant-Jésus, Québec City, Quebec, Canada
🇦🇺
Kinghorn Cancer Centre, St Vincent's Health Network, Darlinghurst, New South Wales, Australia
🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia

and more 6 locations

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: bb2121
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Lenalidomide

First Posted Date: 2019-12-12

Last Posted Date: 2023-08-23

Lead Sponsor: Celgene

Target Recruit Count: 13

Registration Number: NCT04196491

Locations: 🇺🇸
Local Institution - 117, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 108, Atlanta, Georgia, United States
🇺🇸
Local Institution - 110, Los Angeles, California, United States

and more 19 locations

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Phase 2

Recruiting

Conditions: Acute Leukemia
Acute Lymphoblastic Leukemia
Anaplastic Large Cell Lymphoma
Acute Myeloid Leukemia
Adult Diffuse Large Cell Lymphoma
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Prolymphocytic Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cyclosporine
Biological: Filgrastim
Drug: Fludarabine
Drug: Mycophenolate Mofetil
Drug: Mycophenolate Sodium
Radiation: Total-Body Irradiation
Drug: Treosulfan
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Positron Emission Tomography

First Posted Date: 2019-12-12

Last Posted Date: 2024-08-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04195633

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

Phase 1

Recruiting

Conditions: Glioma of Brainstem
Glioma of Spinal Cord

Interventions: Drug: GD2 CAR T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-12-12

Last Posted Date: 2024-10-17

Lead Sponsor: Crystal Mackall, MD

Target Recruit Count: 54

Registration Number: NCT04196413

Locations: 🇺🇸
Lucile Packard Children's Hospital (LPCH), Stanford, California, United States

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Docetaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2019-12-10

Last Posted Date: 2020-03-09

Lead Sponsor: Fudan University

Target Recruit Count: 1560

Registration Number: NCT04193059

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Phase 1

Active, not recruiting

Conditions: Neutropenia
Breast Cancer

Interventions: Biological: Eflapegrastim
Drug: Docetaxel
Drug: Cyclophosphamide

First Posted Date: 2019-12-05

Last Posted Date: 2024-07-11

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 50

Registration Number: NCT04187898

Locations: 🇺🇸
BRCR Medical Center, Inc., Plantation, Florida, United States
🇺🇸
City of Hope, Long Beach, California, United States
🇺🇸
Mercy Health Youngstown, Youngstown, Ohio, United States

and more 5 locations

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Phase 2

Conditions: EBV-Positive DLBCL, Nos

Interventions: Drug: Sintilimab
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone

First Posted Date: 2019-11-29

Last Posted Date: 2019-11-29

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 55

Registration Number: NCT04181489

Locations: 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China
🇨🇳
Drum tower hospital, Nanjing, Jiangsu, China
🇨🇳
Xuzhou Central Hospital, Xuzhou, Jiangsu, China

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy